Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen Inc. (OCGN) is a clinical-stage biopharmaceutical company pioneering gene therapies for retinal diseases and innovative vaccine platforms. This dedicated news hub provides investors and researchers with timely updates on Ocugen’s scientific advancements, regulatory milestones, and strategic initiatives.
Access verified press releases and curated financial news covering clinical trial developments, partnership announcements, and corporate updates. Our repository includes updates on modifier gene therapy programs for conditions like retinitis pigmentosa, inhaled vaccine research, and ocular disorder treatments undergoing regulatory review.
Key content categories include progress reports on Phase I-III trials, FDA designations, intellectual property updates, and financial performance summaries. Bookmark this page for streamlined tracking of OCGN’s advancements in gene editing technologies and mucosal vaccine development.
Ocugen (NASDAQ: OCGN) announced promising results from Bharat Biotech's Phase 3 trial of COVAXIN, indicating a vaccine efficacy of 78% against COVID-19 after two doses. Notably, it showcased 100% efficacy against severe COVID-19 cases and 70% efficacy against asymptomatic infections. The trial involved 25,800 participants, with recent data reflecting 127 symptomatic cases leading to these positive outcomes. COVAXIN has already been administered to millions in India, underlining its critical role in pandemic control.
Ocugen (NASDAQ: OCGN) announced the appointment of John Paul (J.P.) Gabriel as Senior Vice President of Manufacturing and Supply Chain. With over 25 years of experience, Gabriel has held key roles in leading biopharmaceutical companies, including Sanofi Pasteur and Pfizer Vaccines. His expertise will be vital in facilitating the U.S. manufacturing of COVAXIN, a COVID-19 vaccine candidate co-developed by Ocugen. Gabriel is expected to contribute significantly to the technology transfer from Bharat Biotech, enhancing Ocugen's capabilities in the vaccine sector.
Ocugen (NASDAQ: OCGN) announced its participation in a virtual Fireside Chat on March 31, 2021, with Cantor Fitzgerald. CEO Dr. Shankar Musunuri will discuss COVAXIN, a COVID-19 vaccine developed in collaboration with Bharat Biotech, highlighting safety and efficacy data, differences from mRNA vaccines, and pandemic conditions. The presentation aims to identify opportunities for COVAXIN in the U.S., where Ocugen expects to earn 45% of profits from sales.
Ocugen reports a productive year in 2020 with financial results indicating a net loss per share of $0.31, improving from a loss of $1.46 in 2019. The company has made significant strides in developing its COVID-19 vaccine candidate, COVAXIN™, which demonstrated 81% efficacy in Phase 3 trials. Ocugen is pursuing Emergency Use Authorization in the U.S. and has entered a co-development agreement with Bharat Biotech. Additionally, the EC granted orphan medicinal product designation for OCU400, signaling potential in treating retinal diseases. Cash reserves stand at approximately $46.6 million as of February 2021.
Ocugen has announced a conference call to discuss its financial results for 2020 on March 18, 2021, at 8:30 a.m. ET. The biopharmaceutical company focuses on gene therapies to treat blindness and is co-developing Bharat Biotech's COVAXIN for COVID-19 in the U.S. The pre-market earnings announcement will precede the call. Investors can participate via dial-in or webcast, accessible on Ocugen's website for 45 days post-call. This event highlights Ocugen's ongoing commitment to advancing its product candidates and financial transparency.
Ocugen, a biopharmaceutical firm, announced participation in three upcoming conferences: H.C. Wainwright Global Life Sciences Conference (Mar 9-10), 33rd Annual Roth Conference (Mar 15-17), and Oppenheimer 31st Annual Healthcare Conference (Mar 16-18). CEO Dr. Shankar Musunuri will present on COVID-19 vaccine COVAXIN™ and their gene therapy. The H.C. Wainwright conference features a fireside chat, while the Roth Conference includes a panel on COVID-19 therapies. Ocugen focuses on gene therapies for retinal diseases and COVAXIN for the U.S. market.
Ocugen announced promising results from Bharat Biotech's Phase 3 trial of COVAXIN, a COVID-19 vaccine, showing 81% efficacy in preventing symptomatic infections in over 25,800 participants. The interim analysis indicated that the vaccine was well tolerated with few adverse events. COVAXIN demonstrated the ability to neutralize the UK variant, underscoring its potential in the U.S. market. Further analyses are planned as the trial continues, aiming to finalize results at 130 confirmed cases.
Ocugen (NASDAQ: OCGN) has received orphan medicinal product designation from the European Commission for its gene therapy candidate OCU400, aimed at treating retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA). The company estimates that RP affects 165,000 and LCA approximately 40,000 patients in Europe. OCU400 leverages a modifier gene therapy platform that could address multiple inherited retinal diseases, potentially benefiting millions globally. The designation provides significant advantages, including reduced regulatory fees and a decade of market exclusivity.
Ocugen, Inc. (Nasdaq: OCGN) has successfully completed a registered direct offering of 3,000,000 shares of common stock, generating approximately $23 million in gross proceeds. The offering was facilitated by H.C. Wainwright & Co. The funds will primarily support general corporate purposes, including capital expenditures and working capital. The shares were offered under a shelf registration statement filed with the SEC, ensuring compliance with regulatory standards.
Ocugen, Inc. (Nasdaq: OCGN) announced a registered direct offering of 3,000,000 shares of common stock at $7.65 per share, expecting gross proceeds of $23 million. The offering will close around February 10, 2021, subject to customary conditions. The funds raised will be allocated for general corporate purposes, capital expenditures, and working capital. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The shares are being offered under an effective shelf registration statement with the SEC, ensuring compliance with securities laws.
